Senseonics, in collaboration with Ascensia Diabetes Care, has announced that its Eversense product received an integrated continuous glucose monitoring (iCGM) designation from the US Food and Drug Administration (FDA).

This marks Eversense as the first fully implantable device to achieve such status, paving the way for future devices of its kind through the FDA’s De Novo pathway.

The iCGM designation signifies that the system can be integrated with compatible medical devices, such as insulin pumps, to create an automated insulin delivery (AID) system.

With this integration, Eversense can now address the common limitations of AID systems identified in the 2022 Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.

Senseonics president and CEO Tim Goodnow said: “The iCGM designation has been a core component of our strategic initiatives to advance our pipeline, and we are excited to move forward with the next steps to accelerate the integration of the world’s longest-lasting CGM with leading insulin devices.

“The rigorous data requirements for this FDA designation highlight our team’s advanced engineering expertise in developing a CGM that meets high standards. Our confidence in our differentiated technology is high, as there is a tremendous opportunity with iCGM to deliver value and provide substantial benefits to diabetes patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As we look ahead, we are focused on progressing our partnership discussions and software developments, and look forward to providing more updates.”

Senseonics and Ascensia are now set to advance partnership discussions with insulin pump manufacturers, aiming to provide a new interoperable CGM option for those integrating their diabetes management devices.

The Eversense CGM System, designed by Senseonics and distributed by Ascensia, is distinguished by its six-month wear time, accuracy in low glucose ranges, reliable alert detection, and a removable transmitter that does not require sensor wastage or additional warm-up time upon reattachment.

Last September, Senseonics completed the adult cohort of the ENHANCE pivotal clinical trial for Eversense, with the final study subject completing a 365-day visit.

The ENHANCE trial aimed to evaluate the safety and accuracy of the Eversense system over one year.